Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.42 |
| ▸ | HTR3A | P46098 | 5/20 | 0.42 |
| ▸ | HTR3B | O95264 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462012 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBHRH4HTR3AHTR3B | |
| SCHEMBL17269955 | 0.83 | POLB (0.40) | SMN1; SMN2POLBKDM4EMAPT | |
| SCHEMBL24393197 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2POLBKDM4E | |
| SCHEMBL3767624 | 0.79 | MAPK1 (0.42) | SMN1; SMN2KDM4EMAPT | |
| SCHEMBL1491746 | 0.75 | SMN1; SMN2 (0.71) | SMN1; SMN2HRH4HTR3AHTR3BHTR3E | |
| SCHEMBL20810660 | 0.74 | POLB (0.51) | SMN1; SMN2POLBMAPT | |
| SCHEMBL28514042 | 0.73 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBHRH4HTR3AHTR3B | |
| SCHEMBL20182744 | 0.72 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HTR3AHTR3BKDM4E | |
| SCHEMBL17225000 | 0.72 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBHRH4HTR3AHTR3B | |
| SCHEMBL17225022 | 0.71 | SMN1; SMN2 (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4516779-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2024-02-15 | — | — | US | disclosed |
| WO-2023208130-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| EP-4237418-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116685583-A | Pyrimidine compounds, compositions and pharmaceutical uses thereof | 缆图药品公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116496252-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022094354-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094354-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-106255685-B | For preventing or treating the Triaminopyrimidine compound of malaria | MMV疟疾药物投资公司 | 2019-08-20 | — | — | CN | disclosed |
| US-9957253-B2 | Triaminopyrimidine compounds useful for preventing or treating malaria | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9957253-B2 | Triaminopyrimidine compounds useful for preventing or treating malaria | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9957253-B2 | Triaminopyrimidine compounds useful for preventing or treating malaria | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-05-01 | — | — | US | disclosed |
| EP-3137455-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | MMV Medicines for Malaria Venture (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2017-02-23 | — | — | US | disclosed |
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2017-02-23 | — | — | US | disclosed |
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2017-02-23 | — | — | US | disclosed |
| WO-2015165660-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165660-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | TYMP, DPYD, TYMS | SMN1; SMN2 1526/4885POLB 91/4885HRH4 2739/4885 |
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | DPYD, TYMP, DHFR | SMN1; SMN2 2813/4885POLB 334/4885HRH4 2323/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | SMN1; SMN2 2646/4885POLB 512/4885HRH4 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.